|
|
Title | Creator | Description | Identifier |
1 |
|
Tocilizumab in Patients With Giant Cell Arteritis: Results From a Phase 3 Randomized Controlled Trial (abstract) | Susan Mollan, Katie Tuckwell, Sophie Dimonaco, Micki Klearman, Neil Collinson, John Stone | The efficacy and safety of tocilizumab (TCZ), an IL-6 receptor-alpha inhibitor, was evaluated in patients with giant cell arteritis (GCA) in GiACTA, a randomized, double-blind, placebo-controlled trial.1 Data for week 52 outcome measures are presented. | 20170403_nanos_sciplatform1_01-abstract |
2 |
|
Tocilizumab in Patients With Giant Cell Arteritis: Results From a Phase 3 Randomized Controlled Trial (video) | Susan Mollan, Katie Tuckwell, Sophie Dimonaco, Micki Klearman, Neil Collinson, John Stone | The efficacy and safety of tocilizumab (TCZ), an IL-6 receptor-alpha inhibitor, was evaluated in patients with giant cell arteritis (GCA) in GiACTA, a randomized, double-blind, placebo-controlled trial.1 Data for week 52 outcome measures are presented. | 20170403_nanos_sciplatform1_01-video |